Efficacy of curcumin for recurrent aphthous stomatitis: a systematic review.
Curcumin
aphthous stomatitis
efficacy
systematic review
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
pubmed:
8
9
2020
medline:
10
6
2022
entrez:
7
9
2020
Statut:
ppublish
Résumé
Recurrent aphthous stomatitis (RAS) is the most common ulcerative lesion of the oral mucosa. The management of RAS is quite challenging with no definitive cure. The present systematic review aimed to summarize the available evidence regarding the efficacy of curcumin in the management of RAS. PubMed, Scopus and Web of Science databases were searched in June 2020 for all relevant studies. Clinical trials that assessed the efficacy of curcumin for the management of RAS were included. The primary outcomes were pain and/or clinical improvement. Eight studies involving 439 subjects were included. The efficacy of curcumin was compared with 1% triamcinolone in four studies, glycerin vehicle in one study, placebo in one study, and honey in one study. Overall, the included studies reported a good efficacy of curcumin in reducing pain and ulcers size in patients with RAS. Four studies found curcumin as effective as triamcinolone in relieving signs and symptoms of RAS. Three studies reported superior results with curcumin as compared with control groups. The limited available evidence suggests that curcumin have potential benefits in alleviating pain and accelerating healing in patients with RAS. Further well-designed clinical trials with standardized curcumin formulations are highly recommended.
Sections du résumé
BACKGROUND
UNASSIGNED
Recurrent aphthous stomatitis (RAS) is the most common ulcerative lesion of the oral mucosa. The management of RAS is quite challenging with no definitive cure.
OBJECTIVE
UNASSIGNED
The present systematic review aimed to summarize the available evidence regarding the efficacy of curcumin in the management of RAS.
METHODS
UNASSIGNED
PubMed, Scopus and Web of Science databases were searched in June 2020 for all relevant studies. Clinical trials that assessed the efficacy of curcumin for the management of RAS were included. The primary outcomes were pain and/or clinical improvement.
RESULTS
UNASSIGNED
Eight studies involving 439 subjects were included. The efficacy of curcumin was compared with 1% triamcinolone in four studies, glycerin vehicle in one study, placebo in one study, and honey in one study. Overall, the included studies reported a good efficacy of curcumin in reducing pain and ulcers size in patients with RAS. Four studies found curcumin as effective as triamcinolone in relieving signs and symptoms of RAS. Three studies reported superior results with curcumin as compared with control groups.
CONCLUSION
UNASSIGNED
The limited available evidence suggests that curcumin have potential benefits in alleviating pain and accelerating healing in patients with RAS. Further well-designed clinical trials with standardized curcumin formulations are highly recommended.
Identifiants
pubmed: 32893718
doi: 10.1080/09546634.2020.1819529
doi:
Substances chimiques
Triamcinolone
1ZK20VI6TY
Curcumin
IT942ZTH98
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM